NAV

Bioymifi

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Bioymifi
DrugBank Accession Number
DB17493
Background

Bioymifi is a small molecule that acts as a tumor necrosis factor-related apoptosis-induced ligand (TRAIL) mimetic. Upon binding to the death receptor 5 (DR5) on cancer cells, bioymifi triggers apoptosis, possibly through a caspase-dependent pathway. Bioymifi is currently being investigated as an anti-tumor agent.1,2

Type
Small Molecule
Groups
Investigational
Structure
Similar Structures
Weight
Average: 494.32
Monoisotopic: 492.97319
Chemical Formula
C22H12BrN3O4S
Synonyms
  • 5-(5-((3-(4-bromophenyl)-2-imino-4-oxothiazolidin-5-ylidene)methyl)furan-2-yl)isoindoline-1,3-dione
  • 5-[5-[(Z)-[3-(4-bromophenyl)-2-imino-4-oxo-1,3-thiazolidin-5-ylidene]methyl]furan-2-yl]isoindole-1,3-dione
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action

In cancer cells, tumor necrosis factor (TNF)-related apoptosis-induced ligand (TRAIL) initiates apoptosis by binding to death receptor 5 (DR5). In contrast, normal cells express high levels of decoy receptors (DcRs) that partially or completely lack the functional death domain (DD). Therefore, the binding of TRAIL on normal cells does not induce cell death.3 Because of this, small molecules that mimic the activity of TRAIL may have the potential to act as chemotherapeutic agents. Bioymifi mimics the activity of TRAIL, and upon binding to the extracellular domain (ECD) of DR5, it induces clustering and aggregation in cancer cells, leading to apoptosis.1,2

TargetActionsOrganism
UTumor necrosis factor receptor superfamily member 10B
binder
Humans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
1420071-30-2
InChI Key
ULBOWKXOFOTCMU-CPEDPXAASA-N
InChI
InChI=1S/C22H12BrN3O4S/c23-12-2-4-13(5-3-12)26-21(29)18(31-22(26)24)10-14-6-8-17(30-14)11-1-7-15-16(9-11)20(28)25-19(15)27/h1-10,24H,(H,25,27,28)/b18-10-,24-22+
IUPAC Name
6-(5-{[(5Z)-3-(4-bromophenyl)-2-imino-4-oxo-1,3-thiazolidin-5-ylidene]methyl}furan-2-yl)-3-hydroxy-1H-isoindol-1-one
SMILES
[H]N=C1S\C(=C(\[H])C2=CC=C(O2)C2=CC3=C(C=C2)C(O)=NC3=O)C(=O)N1C1=CC=C(Br)C=C1

References

General References
  1. Wang G, Wang X, Yu H, Wei S, Williams N, Holmes DL, Halfmann R, Naidoo J, Wang L, Li L, Chen S, Harran P, Lei X, Wang X: Small-molecule activation of the TRAIL receptor DR5 in human cancer cells. Nat Chem Biol. 2013 Feb;9(2):84-9. doi: 10.1038/nchembio.1153. Epub 2012 Dec 23. [Article]
  2. Alfhili MA, Basudan AM, Aljaser FS, Dera A, Alsughayyir J: Bioymifi, a novel mimetic of TNF-related apoptosis-induced ligand (TRAIL), stimulates eryptosis. Med Oncol. 2021 Oct 11;38(12):138. doi: 10.1007/s12032-021-01589-5. [Article]
  3. Min KJ, Woo SM, Shahriyar SA, Kwon TK: Elucidation for modulation of death receptor (DR) 5 to strengthen apoptotic signals in cancer cells. Arch Pharm Res. 2019 Jan;42(1):88-100. doi: 10.1007/s12272-018-01103-y. Epub 2019 Jan 10. [Article]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0395 mg/mLALOGPS
logP3.76ALOGPS
logP4.23Chemaxon
logS-4.1ALOGPS
pKa (Strongest Acidic)6.07Chemaxon
pKa (Strongest Basic)1.6Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area106.96 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity131.97 m3·mol-1Chemaxon
Polarizability46.34 Å3Chemaxon
Number of Rings5Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Tumor necrosis factor receptor superfamily member 10B
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Binder
General Function
Tumor necrosis factor-activated receptor activity
Specific Function
Receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 pro...
Gene Name
TNFRSF10B
Uniprot ID
O14763
Uniprot Name
Tumor necrosis factor receptor superfamily member 10B
Molecular Weight
47877.885 Da
References
  1. Wang G, Wang X, Yu H, Wei S, Williams N, Holmes DL, Halfmann R, Naidoo J, Wang L, Li L, Chen S, Harran P, Lei X, Wang X: Small-molecule activation of the TRAIL receptor DR5 in human cancer cells. Nat Chem Biol. 2013 Feb;9(2):84-9. doi: 10.1038/nchembio.1153. Epub 2012 Dec 23. [Article]
  2. Alfhili MA, Basudan AM, Aljaser FS, Dera A, Alsughayyir J: Bioymifi, a novel mimetic of TNF-related apoptosis-induced ligand (TRAIL), stimulates eryptosis. Med Oncol. 2021 Oct 11;38(12):138. doi: 10.1007/s12032-021-01589-5. [Article]

Drug created at February 03, 2023 21:27 / Updated at February 05, 2024 00:29